vs
Side-by-side financial comparison of Marygold Companies, Inc. (MGLD) and STRATA Skin Sciences, Inc. (SSKN). Click either name above to swap in a different company.
STRATA Skin Sciences, Inc. is the larger business by last-quarter revenue ($9.3M vs $7.6M, roughly 1.2× Marygold Companies, Inc.). STRATA Skin Sciences, Inc. runs the higher net margin — 0.6% vs -7.5%, a 8.2% gap on every dollar of revenue. On growth, STRATA Skin Sciences, Inc. posted the faster year-over-year revenue change (-3.0% vs -4.5%). Over the past eight quarters, STRATA Skin Sciences, Inc.'s revenue compounded faster (17.3% CAGR vs -1.5%).
Marygold Companies, Inc. is a U.S.-headquartered diversified holding company that operates across three core segments: financial services, specialty manufacturing, and consumer goods. It primarily caters to North American markets, driving long-term value growth via strategic investment in, and operational optimization of, its portfolio of subsidiary entities.
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
MGLD vs SSKN — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $7.6M | $9.3M |
| Net Profit | $-576.0K | $58.0K |
| Gross Margin | 74.0% | 61.8% |
| Operating Margin | -8.3% | 5.3% |
| Net Margin | -7.5% | 0.6% |
| Revenue YoY | -4.5% | -3.0% |
| Net Profit YoY | 67.0% | 101.3% |
| EPS (diluted) | $-0.01 | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $7.6M | $9.3M | ||
| Q3 25 | $7.0M | $6.9M | ||
| Q2 25 | $7.2M | $7.7M | ||
| Q1 25 | $7.0M | $6.8M | ||
| Q4 24 | $8.0M | $9.6M | ||
| Q3 24 | $7.9M | $8.8M | ||
| Q2 24 | $8.3M | $8.4M | ||
| Q1 24 | $7.9M | $6.8M |
| Q4 25 | $-576.0K | $58.0K | ||
| Q3 25 | $-356.0K | $-1.6M | ||
| Q2 25 | $-1.5M | $-2.6M | ||
| Q1 25 | $-1.0M | $-2.1M | ||
| Q4 24 | $-1.7M | $-4.6M | ||
| Q3 24 | $-1.6M | $-2.1M | ||
| Q2 24 | $-1.9M | $-91.0K | ||
| Q1 24 | $-529.0K | $-3.4M |
| Q4 25 | 74.0% | 61.8% | ||
| Q3 25 | 77.0% | 60.4% | ||
| Q2 25 | 67.8% | 56.2% | ||
| Q1 25 | 75.0% | 53.5% | ||
| Q4 24 | 74.1% | 61.4% | ||
| Q3 24 | 73.1% | 60.1% | ||
| Q2 24 | 72.5% | 59.0% | ||
| Q1 24 | 70.5% | 45.6% |
| Q4 25 | -8.3% | 5.3% | ||
| Q3 25 | -18.2% | -16.9% | ||
| Q2 25 | -16.5% | -30.1% | ||
| Q1 25 | -21.4% | -25.0% | ||
| Q4 24 | -22.8% | -44.7% | ||
| Q3 24 | -27.4% | -18.2% | ||
| Q2 24 | -33.3% | -5.7% | ||
| Q1 24 | -18.7% | -42.7% |
| Q4 25 | -7.5% | 0.6% | ||
| Q3 25 | -5.1% | -23.4% | ||
| Q2 25 | -20.4% | -33.6% | ||
| Q1 25 | -14.4% | -31.2% | ||
| Q4 24 | -21.8% | -47.6% | ||
| Q3 24 | -20.1% | -23.6% | ||
| Q2 24 | -22.5% | -1.1% | ||
| Q1 24 | -6.7% | -49.8% |
| Q4 25 | $-0.01 | $0.14 | ||
| Q3 25 | $-0.01 | $-0.36 | ||
| Q2 25 | $-0.04 | $-0.62 | ||
| Q1 25 | $-0.02 | $-0.51 | ||
| Q4 24 | $-0.04 | $-2.01 | ||
| Q3 24 | $-0.04 | $-0.51 | ||
| Q2 24 | $-0.05 | $-0.03 | ||
| Q1 24 | $-0.01 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $11.6M | $7.9M |
| Total DebtLower is stronger | — | $15.3M |
| Stockholders' EquityBook value | $22.7M | $2.9M |
| Total Assets | $27.8M | $30.5M |
| Debt / EquityLower = less leverage | — | 5.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.6M | $7.9M | ||
| Q3 25 | $12.5M | $7.1M | ||
| Q2 25 | $12.8M | $6.0M | ||
| Q1 25 | $15.6M | $6.5M | ||
| Q4 24 | $14.9M | $7.3M | ||
| Q3 24 | $17.5M | $7.1M | ||
| Q2 24 | $15.0M | $5.5M | ||
| Q1 24 | $16.1M | $5.2M |
| Q4 25 | — | $15.3M | ||
| Q3 25 | — | $15.3M | ||
| Q2 25 | — | $15.0M | ||
| Q1 25 | — | $15.0M | ||
| Q4 24 | — | $15.0M | ||
| Q3 24 | — | $15.0M | ||
| Q2 24 | — | $15.0M | ||
| Q1 24 | — | $15.0M |
| Q4 25 | $22.7M | $2.9M | ||
| Q3 25 | $22.9M | $1.3M | ||
| Q2 25 | $23.0M | $532.0K | ||
| Q1 25 | $24.3M | $3.0M | ||
| Q4 24 | $23.4M | $5.0M | ||
| Q3 24 | $25.5M | $9.4M | ||
| Q2 24 | $26.6M | $9.5M | ||
| Q1 24 | $28.4M | $9.4M |
| Q4 25 | $27.8M | $30.5M | ||
| Q3 25 | $28.4M | $30.7M | ||
| Q2 25 | $30.4M | $29.5M | ||
| Q1 25 | $33.5M | $33.0M | ||
| Q4 24 | $33.0M | $34.9M | ||
| Q3 24 | $35.9M | $39.4M | ||
| Q2 24 | $32.9M | $38.8M | ||
| Q1 24 | $33.7M | $39.2M |
| Q4 25 | — | 5.28× | ||
| Q3 25 | — | 11.65× | ||
| Q2 25 | — | 28.20× | ||
| Q1 25 | — | 5.04× | ||
| Q4 24 | — | 3.02× | ||
| Q3 24 | — | 1.60× | ||
| Q2 24 | — | 1.58× | ||
| Q1 24 | — | 1.59× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-908.0K | $-239.0K |
| Free Cash FlowOCF − Capex | — | $-551.0K |
| FCF MarginFCF / Revenue | — | -5.9% |
| Capex IntensityCapex / Revenue | 0.0% | 3.4% |
| Cash ConversionOCF / Net Profit | — | -4.12× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-4.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-908.0K | $-239.0K | ||
| Q3 25 | $-533.0K | $-64.0K | ||
| Q2 25 | $-3.3M | $-1.9M | ||
| Q1 25 | $-1.2M | $-550.0K | ||
| Q4 24 | $-770.0K | $703.0K | ||
| Q3 24 | $-893.0K | $-302.0K | ||
| Q2 24 | $-1.9M | $591.0K | ||
| Q1 24 | $-658.0K | $-804.0K |
| Q4 25 | — | $-551.0K | ||
| Q3 25 | $-562.0K | $-1.1M | ||
| Q2 25 | $-3.4M | $-2.0M | ||
| Q1 25 | — | $-749.0K | ||
| Q4 24 | $-776.0K | $199.0K | ||
| Q3 24 | $-940.0K | $-364.0K | ||
| Q2 24 | $-2.0M | $246.0K | ||
| Q1 24 | — | $-1.5M |
| Q4 25 | — | -5.9% | ||
| Q3 25 | -8.1% | -15.6% | ||
| Q2 25 | -46.8% | -26.1% | ||
| Q1 25 | — | -11.0% | ||
| Q4 24 | -9.7% | 2.1% | ||
| Q3 24 | -11.9% | -4.1% | ||
| Q2 24 | -23.8% | 2.9% | ||
| Q1 24 | — | -22.6% |
| Q4 25 | 0.0% | 3.4% | ||
| Q3 25 | 0.4% | 14.7% | ||
| Q2 25 | 0.7% | 0.8% | ||
| Q1 25 | 0.0% | 2.9% | ||
| Q4 24 | 0.1% | 5.3% | ||
| Q3 24 | 0.6% | 0.7% | ||
| Q2 24 | 0.7% | 4.1% | ||
| Q1 24 | 0.0% | 10.7% |
| Q4 25 | — | -4.12× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MGLD
| Fund Management Related Party | $4.6M | 60% |
| Food Products | $1.7M | 22% |
| Beauty Products | $1.2M | 15% |
| Other | $268.0K | 4% |
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
